Universal CAR T cells produce rapid remissions and enable allogeneic stem cell transplants in patients with relapsed or refractory T-cell acute lymphoblastic leukemia.

Chimeric antigen receptor T (CAR-T) cell therapy has revolutionized hematologic cancer treatment, but its efficacy in solid tumors remains limited by poor infiltration into the complex tumor ...

T-MAXIMUM is currently focused on late-stage malignant tumors, and its lead program for recurrent glioma has received clearance to enter Phase II clinical trials. Over the next three years, the ...

At the recent American Society of Hematology annual meeting, phase I data highlighted a next-generation, CD19-targeted, interleukin-18-secreting "armored" CAR T-cell therapy that is designed to ...

CRISPR Therapeutics shares early autoimmune and lymphoma data for zugo-cel, showing strong responses, manageable safety, and ...

Recreation of CAR-T cells attacking a cancerous melanoma cell. Nemes Laszlo/Shutterstock Personalised medicine is already a reality in clinical practice, and CAR-T cell therapy is one of its most ...

Two recent studies show the novel therapy works in people with multiple myeloma, but researchers are trying to minimize side ...

ORLANDO -- A gene therapy that could transform CAR T-cell treatment achieved rapid and potentially durable measurable ...

Cell therapy company Link Cell Therapies is launching with $60 million and a mission to develop potent CAR-T therapies that ...

The Food and Drug Administration (FDA) has approved Breyanzi ® (lisocabtagene maraleucel; liso-cel) for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) ...

Safety and efficacy data from a phase 1 multicenter study evaluating rapcabtagene autoleucel, an investigational ...

Ever notice that as you get older, some foods no longer sit with you the same? This could be due to a breakdown of the ...